KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$5.85 USD
+0.10 (1.74%)
Updated Aug 9, 2024 02:29 PM ET
After-Market: $5.92 +0.07 (1.20%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth B Momentum D VGM
Brokerage Reports
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 61 - 80 ( 367 total )
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS-& EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: ARGYRIDES A
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Eyes Wide Open: Setting Our Sights on a New Frontier in Ocular Disease
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Shifting Focus to Value-Driving Assets; Assuming Coverage at OUTPERFORM & $6 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Shifting Focus to Value-Driving Assets; Assuming Coverage at OUTPERFORM & $6 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS EYSUVIS?
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q3: EYSUVIS & INVELTYS Plagued by Pandemic Headwinds; Pipeline Expands
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Orphan Drug Acquired; 3Q21 Results; Reiterate Buy; Modulating PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS & EYSUVIS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L